<?xml version="1.0" encoding="UTF-8"?>
<collection>
<dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:invenio="http://invenio-software.org/elements/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:identifier>doi:10.3390/cancers14081983</dc:identifier><dc:language>eng</dc:language><dc:creator>Ayuso, J. M.</dc:creator><dc:creator>Ochoa Garrido, I.</dc:creator><dc:title>The importance of the tumor microenvironment to understand tumor origin, evolution, and treatment response</dc:title><dc:identifier>ART-2022-129195</dc:identifier><dc:description>During the second half of the twentieth century, oncology adopted a tumor-centric approach to cancer treatment, focusing primarily on the tumor cell to identify new therapeutic targets. However, since the 2000s, we have seen a gradual shift in this paradigm with numerous studies highlighting the importance of the tumor microenvironment in tumor progression, patient prognosis, and therapy response. Solid tumors are highly complex systems where numerous cell types and microenvironmental factors are intertwined, potentially affecting tumor evolution, treatment response, and patient outcome. Stromal cells such as fibroblasts and immune cells can stimulate or suppress tumor growth and are currently being used as therapeutic targets in numerous studies and clinical trials...</dc:description><dc:date>2022</dc:date><dc:source>http://zaguan.unizar.es/record/117979</dc:source><dc:doi>10.3390/cancers14081983</dc:doi><dc:identifier>http://zaguan.unizar.es/record/117979</dc:identifier><dc:identifier>oai:zaguan.unizar.es:117979</dc:identifier><dc:identifier.citation>Cancers 14, 8 (2022), 1983 [4 pp.]</dc:identifier.citation><dc:rights>by</dc:rights><dc:rights>http://creativecommons.org/licenses/by/3.0/es/</dc:rights><dc:rights>info:eu-repo/semantics/openAccess</dc:rights></dc:dc>

</collection>